Suppr超能文献

肾移植术后B型主动脉夹层的胸主动脉腔内修复术

Thoracic endovascular aortic repair for type B aortic dissection after renal transplantation.

作者信息

Shu Chang, Xiong QingGen, Qiu Jian, Luo MingYao, Fang Kun

机构信息

Department of Vascular Surgery, The Second Xiangya Hospital of Central South University, Changsha, 410011, China.

Center of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China.

出版信息

Oncotarget. 2017 Sep 30;8(53):91628-91635. doi: 10.18632/oncotarget.21399. eCollection 2017 Oct 31.

Abstract

Thoracic endovascular repair (TEVAR) is an effective treatment for type B aortic dissection (TBAD). Here, we evaluated the early-midterm effectiveness and safety of TEVAR for treating TBAD patients after renal transplantation. Six patients with TBAD treated with TEVAR after renal transplantation were recruited between February 2012 and December 2016. They were then followed up with clinical examinations and computed tomography angiography (CTA). TEVAR was successfully performed in all patients (100%), and the primary tear sites were well covered by stents with or without coverage of the left subclavian artery. No severe complications occurred in any patient during perioperative period. The one-year survival rate was 100%, one patient died of renal graft failure and heart failure four years after TEVAR; the remaining five patients (83.3%) survived and exhibited no severe complications. Our findings show that TEVAR provides satisfactory short-midterm results for TBAD patients after renal transplantation. Moreover, our experience shows that it need relative longer proximal landing zone to prevent the endoleak and recurrence. However, regular hematodialysis, long-term immunosuppressive therapy, and blood pressure control remain crucial factors to prolong survival. Long-term follow-up studies are needed to evaluate the long-term prognosis in these patients.

摘要

胸主动脉腔内修复术(TEVAR)是治疗B型主动脉夹层(TBAD)的一种有效方法。在此,我们评估了TEVAR治疗肾移植术后TBAD患者的早中期疗效及安全性。2012年2月至2016年12月期间,招募了6例肾移植术后接受TEVAR治疗的TBAD患者。随后对他们进行临床检查及计算机断层扫描血管造影(CTA)随访。所有患者(100%)均成功实施了TEVAR,原发破口部位均被支架良好覆盖,部分患者左锁骨下动脉也被覆盖。围手术期无患者发生严重并发症。1年生存率为100%,1例患者在TEVAR术后4年死于肾移植失败及心力衰竭;其余5例患者(83.3%)存活,且无严重并发症。我们的研究结果表明,TEVAR为肾移植术后TBAD患者提供了满意的短中期疗效。此外,我们的经验表明,需要相对更长的近端锚定区以预防内漏及复发。然而,规律血液透析、长期免疫抑制治疗及血压控制仍是延长生存的关键因素。需要进行长期随访研究以评估这些患者的长期预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a603/5710952/3369184ec46e/oncotarget-08-91628-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验